Materials and methods for treatment of pain related disorders
AssigneeCrispr Therapeutics AG
InventorsAnte Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan
Life of this patent
Estimating the term…
Abstract
The present application provides materials and methods for treating a patient with one or more conditions associated with SCN9A whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of SCN9A gene in a cell by genome editing.
Claims39
A method for editing a Sodium Voltage-Gated Channel Alpha Subunit 9 (SCN9A) gene in a cell by genome editing comprising:
- introducing into the cell one or more deoxyribonucleic acid (DNA) endonucleases to effect one or more single-strand breaks (SSBs) or double-strand breaks (DSBs) within or near the SCN9A gene or SCN9A regulatory elements that results in one or more permanent insertions, deletions or mutations of at least one nucleotide within or near the SCN9A gene, thereby reducing or eliminating the expression or function of SCN9A gene products.
An ex vivo method for treating a patient having an SCN9A related condition or disorder comprising:
- (a) editing a patient specific induced pluripotent stem cell (iPSC) within or near a Sodium Voltage-Gated Channel Alpha Subunit 9 (SCN9A) gene or other DNA sequences that encode regulatory elements of the SCN9A gene;
- (b) differentiating the edited iPSC into a neuron of the peripheral nervous system;
- and
- (c) administering said neuron of the peripheral nervous system to the patient.
An ex vivo method for treating a patient having an SCN9A related condition or disorder comprising:
- (a) editing a mesenchymal stem cell within or near a Sodium Voltage-Gated Channel Alpha Subunit 9 (SCN9A) gene or other DNA sequences that encode regulatory elements of the SCN9A gene;
- (b) differentiating the edited mesenchymal stem cell into a neuron of the peripheral nervous system;
- and
- (c) administering the neuron of the peripheral nervous system to the patient.
An in vivo method for treating a patient with an SCN9A related disorder comprising:
- editing the Sodium Voltage-Gated Channel Alpha Subunit 9 (SCN9A) gene in a cell of the patient.
A method of altering the contiguous genomic sequence of an SCN9A gene in a cell comprising:
- contacting said cell with one or more deoxyribonucleic acid (DNA) endonuclease to effect one or more single-strand breaks (SSBs) or double-strand breaks (DSBs).
A single-molecule guide RNA comprising:
- at least a spacer sequence that is an RNA sequence corresponding to any of SEQ ID NOs:
- 5305-125469.
Dependencies are inferred from the claim text.